# A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

> **NCT00376168** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Plant cell expressed recombinant glucocerebrosidase (prGCD)
- **DRUG:** Plant cell expressed recombinant glucocerebrosidase (prGCD)

## Key facts

- **NCT ID:** NCT00376168
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376168, "A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00376168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*